ProQR Therapeutics (PRQR) Equity Average (2018 - 2023)

ProQR Therapeutics' Equity Average history runs 6 years deep, the most recent figure standing at $47.5 million for Q4 2023.

• In Q4 2023, Equity Average fell 28.85% year-over-year to $47.5 million; the TTM figure through Dec 2023 stood at $47.5 million (down 28.85% YoY), while the FY2025 annual figure was $76.1 million, up 9.3% from the prior year.
• Equity Average came in at $47.5 million for Q4 2023 at ProQR Therapeutics, down from $53.4 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $146.9 million in Q3 2021 to a low of $33.7 million in Q1 2021.
• A 5-year average of $79.3 million and a median of $73.4 million in 2019 frame the typical range for Equity Average.
• Across the five-year window, Equity Average surged 434.84% in 2019 and plunged 65.26% in 2021, its largest moves.
• ProQR Therapeutics' Equity Average stood at $85.2 million in 2019, then fell by 13.43% to $73.8 million in 2020, then soared by 91.22% to $141.1 million in 2021, then plunged by 52.7% to $66.7 million in 2022, then slipped by 28.85% to $47.5 million in 2023.
• According to Business Quant data, Equity Average over the past three periods registered $47.5 million, $53.4 million, and $59.9 million for Q4 2023, Q3 2023, and Q2 2023 respectively.

Peer Comparison